Product news from the 10/21/05 News Brief

Share this article:

The FDA approved the expanded use of GlaxoSmithKline's Havrix (hepatitis A vaccine, inactivated) for the prevention of hepatitis A in children aged 12 months and older. Havrix was previously approved by the FDA for use in children ages two through 18 years. This expanded indication will allow healthcare practitioners to vaccinate younger children against hepatitis A with Havrix.

Esprit Pharma acquired exclusive North American rights to Estrasorb (estradiol topical emulsion) from Novavax. A topical emulsion form of the naturally occurring hormone beta-estradiol 17, Estrasorb is the first prescription topical emulsion for estrogen therapy.

Upsher-Smith Laboratories introduced new Vandazole (metronidazole vaginal gel, 0.75 percent) for treatment of bacterial vaginosis in non-pregnant patients.

Share this article:

Email Newsletters

More in Business Briefs

Miss Idaho shows off diabetes pump

NPR reports that the move has made Sierra Sandison a type 1 diabetes hero and that users have given the Facebook photo over 4,000 "likes."

Roche is hungry, not starving for M&A

CEO Severin Schwan tells Reuters that the Swiss firm will be looking for small acquisitions and partnerships.

AbbVie nabs Shire for $54B

AbbVie, in the latest example of a US drugmaker seeking to lower its tax rate, said today that it's buying Dublin-based Shire for $54 billion.